Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state medicaid program

Journal of Managed Care Pharmacy

Volumn 12, Issue 6, 2006, Pages 449-456

  Hamer, Ann M ^b   Hartung, Daniel M ^b   Haxby, Dean G ^a,b   Ketchum, Kathy L ^b   Pollack, David A ^c  

^a Department of Pharmacy ^*

^b OREGON STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dose optimization; Prescription change forms; Selective serotonin reuptake inhibitors; Tablet splitting

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ANTIDEPRESSANT AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG USE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MEDICAID; OUTCOME ASSESSMENT; PRESCRIPTION; TREATMENT OUTCOME; CLINICAL PRACTICE; COST CONTROL; DRUG UTILIZATION; ECONOMICS; HEALTH CARE QUALITY; METHODOLOGY; STATISTICAL MODEL; TABLET; UNITED STATES;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST SAVINGS; DRUG COSTS; DRUG UTILIZATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LINEAR MODELS; MEDICAID; MODELS, ECONOMIC; OREGON; PAROXETINE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROGRAM EVALUATION; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TABLETS;

EID: 34548645711     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.6.449     Document Type: Article

References (12)

1. Soumerai S. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. J Clin Psychiatry. 2003;64(suppl 17):19-22.
2. Cohen CI, Cohen SI. Potential savings from splitting newer antidepressant medications. CNS Drugs. 2002;16(5):353-58.
3. Polli JE, Kim S, Martin BR. Weight uniformity of split tablets required by a Veterans Affairs policy. J Manag Care Pharm. 2003;9(5):401-07.
4. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-85.
5. Dobscha SK, Anderson TA, Hoffman WF et al. Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center. Psychiatry Serv. 2003;54(2):195-200.
6. Calabrese DC, Baldinger SL. Dose-optimization intervention yields significant drug cost savings. J Manag Care Pharm. 2002;8(2):146-51.
7. Curtiss FR, Dose optimization: an opportunity for pharmacy administrative services. J Manag Care Pharm. 2002;8(2):81-82.
8. Curtiss FR, Evidence-based medicine: are SSRIs more effective than placebo and what length of therapy is enough? J Manag Care Pharm. 2005;11(2):172-76, 77-78.
9. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
10. U.S. Food and Drug Administration. Center for Drug Evaluation and Research First-time Generics - October 2004. October 28, 2004, Available at: http://www.fda.gov/cder/ogd/approvals/1stgen1004.htm. Accessed March 6, 2006.
11. Delate T, Fairman KA, Carey SM, Motheral BR. Randomized controlled trial of a dose consolidation program. J Manag Care Pharm. 2004;10(5):396-403.
12. Gee M, Hasson NK, Hahn T, Ryono R. Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance. J Manag Care Pharm. 2002;8(6):453-58.